Company Intelligence
Hengrui Medicine
恒瑞医药
No Known BCC Exposure
Hengrui is a drug innovator, not a CDMO/CRO. It is not on the Section 1260H list and faces no current BIOSECURE exposure. Licensing deals with Hengrui do not create federal contracting risk.
Overview
Hengrui Medicine (恒瑞医药) is China's largest innovative pharmaceutical company by market capitalization. Originally a generics manufacturer, Hengrui pivoted to innovation around 2018 and now maintains one of the deepest oncology and autoimmune pipelines among Chinese biotechs. The company has become the template for large-scale China-to-West portfolio licensing deals.
Key Facts
- GSK deal (Jul 2025): $500M upfront + $12B biobucks across 12 programs in respiratory, immunology, and oncology
- Pipeline includes 60+ clinical-stage candidates across oncology, autoimmune, and metabolic diseases
- R&D spend exceeded $1B in 2025 — highest among Chinese pharma companies
- Shifted from single-asset out-licensing to portfolio framework deals
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| GSK | Jul 2025 | $500M upfront / $12B biobucks | 12 programs: respiratory (HRS-9821 PDE3/4i), immunology, oncology |
| Merck | 2025 | $1.1B | PARP inhibitor (undisclosed) |
Corporate Structure
Publicly listed on Shanghai Stock Exchange. Jiangsu Hengrui Pharmaceuticals Co., Ltd. is the operating entity. No VIE structure. Controlled by founder Sun Piaoyang (孙飘扬) and family.